ЭФФЕКТИВНОСТЬ И СКЛОННОСТЬ К ЛЕЧЕНИЮ ФИКСИРОВАННОЙ ТРОЙНОЙ ТЕРАПИИ ПЕРИНОПРИЛ АРГИНИН / ИНДАПАМИД / АЛЛОДИПИН В НЕРЕГУЛИРУЕМОЙ ЦЕЛЕВОЙ ГРУППЕ, ПОЛУЧАЮЩЕЙ ДВУХКОМПОНЕНТНОЕ ЛЕЧЕНИЕ ЧЛЕНОВ ОРГАНИЗОВАННОЙ ПОПУЛЯЦИИ
Ключевые слова:
ЭФФЕКТИВНОСТЬ, СКЛОННОСТЬ, ТРОЙНОЙ ТЕРАПИИ
Аннотация
Артериальная гипертония (АГ) все еще остается основным фактором риска сердечнососудистых заболеваний.Имеются четкие данные, подтверждающие, что снижение артериального давления (АД) у пациентов с АГ стабильно снижает заболеваемость и смертность от (ССЗ) сердечно-сосудистых заболеваний [1]–[9]. Неоднократно подтверждено, что с изменением образа жизни и выбором правильной тактики медикаментозного лечения можно добиться целевого снижения АД. Несмотря на это, контроль АГ по всему миру все еще остается недостаточным и далек от желаемого результата.
Литература
[1] D. Ettehad et al., “Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis,” Lancet, vol. 387, no. 10022, pp. 957–967, Mar. 2016, doi: 10.1016/S0140-6736(15)01225-8.
[2] M. H. Forouzanfar et al., “Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015,” JAMA, vol. 317, no. 2, pp. 165–182, Jan. 2017, doi: 10.1001/jama.2016.19043.
[3] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, “Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies,” Lancet, vol. 360, no. 9349, pp. 1903–1913, Dec. 2002, doi: 10.1016/S01406736(02)11911-8.
[4] B. Zhou et al., “Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with
19·1 million participants,” Lancet, vol. 389, no. 10064, pp. 37–55, Jan. 2017, doi: 10.1016/S01406736(16)31919-5.
[5] M. J. O’Donnell et al., “Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.,” Lancet (London, England), vol. 388, no. 10046, pp. 761–775, Aug. 2016, doi: 10.1016/S0140-6736(16)30506-2.
[6] E. Rapsomaniki et al., “Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people,” Lancet, vol. 383, no. 9932, pp. 1899–1911, May 2014, doi: 10.1016/S0140-6736(14)60685-1.
[7] C. Thomopoulos, G. Parati, and A. Zanchetti, “Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and meta-regression analyses of randomized trials.,” J. Hypertens., vol. 32, no. 12, pp. 2285–2295, Dec. 2014, doi: 10.1097/HJH.0000000000000378.
[8] W.-C. Tsai et al., “Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Metaanalysis.,” JAMA Intern. Med., vol. 177, no. 6, pp. 792–799, Jun. 2017,
doi: 10.1001/jamainternmed.2017.0197.
[9] S. Yusuf et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.,” Lancet (London, England), vol. 364, no. 9438, pp. 937–952, Sep. 2004, doi: 10.1016/S0140-6736(04)17018-9.
[10] J. R. Banegas et al., “Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.,” Eur. Heart J., vol. 32, no. 17, pp. 2143–2152, Sep. 2011, doi:
10.1093/eurheartj/ehr080.
[11] C. K. Chow et al., “Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.,” JAMA, vol. 310, no. 9, pp. 959–968, Sep. 2013, doi: 10.1001/jama.2013.184182.
[12] E. Falaschetti, J. Mindell, C. Knott, and N. Poulter, “Hypertension management in England: a serial cross-sectional study from 1994 to 2011,” Lancet, vol. 383, no. 9932, pp. 1912–1919, May 2014, doi: 10.1016/S0140-6736(14)60688-7.
[13] G. Tocci et al., “Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension.,” J. Hypertens., vol. 30, no. 6, pp.
1065–1074, Jun. 2012, doi:
10.1097/HJH.0b013e3283535993.
[14] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data.,” Lancet (London, England), vol. 365, no. 9455, pp. 217–223, Jan. 2005, doi: 10.1016/S0140-6736(05)17741-1.
[15] Y. R. Wang, G. C. Alexander, and R. S. Stafford, “Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.,” Arch. Intern. Med., vol. 167, no. 2, pp. 141–147, Jan. 2007, doi: 10.1001/archinte.167.2.141.
[16] G. Corrao et al., “Better compliance to antihypertensive medications reduces cardiovascular risk.,” J. Hypertens., vol. 29, no. 3, pp. 610–618, Mar. 2011, doi: 10.1097/HJH.0b013e328342ca97.
[17] G. A. Mensah and G. Bakris, “Treatment and control of high blood pressure in adults.,” Cardiol. Clin., vol. 28, no. 4, pp. 609–622, Nov. 2010, doi: 10.1016/j.ccl.2010.08.002.
[18] P. Gupta et al., “Risk Factors for Nonadherence to Antihypertensive Treatment.,” Hypertens. (Dallas, Tex. 1979), vol. 69, no. 6, pp.
1113–1120, Jun. 2017, doi:
10.1161/HYPERTENSIONAHA.116.08729.
[19] J. van Gijn, “The PROGRESS Trial: preventing strokes by lowering blood pressure in patients with cerebral ischemia. Emerging therapies:
critique of an important advance.,” Stroke, vol. 33, no. 1, pp. 319–320, Jan. 2002.
[20] C. John et al., “Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus,” Hypertension, vol. 63, no. 2, pp. 259–264, Feb. 2014, doi: 10.1161/HYPERTENSIONAHA.113.02252.
[21] L. Opie, Ed., “No Title,” in Drugs for the heart, 4th ed., Philadelphia: WB Saunders Co., 1995, pp. 50–82.
[22] J. Webster, O. J. Robb, T. A. Jeffers, A. K. Scott, J. C. Petrie, and H. M. Towler, “Once daily amlodipine in the treatment of mild to moderate hypertension.,” Br. J. Clin. Pharmacol., vol. 24, no. 6, pp. 713–719, Dec. 1987, doi: 10.1111/j.13652125.1987.tb03236.x.
[23] B. Dahlof et al., “Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.,” Lancet (London, England), vol. 359, no. 9311, pp. 995–1003, Mar. 2002, doi: 10.1016/S0140-6736(02)08089-3.
[24] L. H. Lindholm et al., “Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol,” Lancet, vol. 359, no. 9311, pp. 1004–1010, Mar. 2002, doi: 10.1016/S0140-6736(02)08090-X.
[25] S. See, “Angiotensin II receptor blockers for the treatment of hypertension.,” Expert Opin. Pharmacother., vol. 2, no. 11, pp. 1795–1804, Nov.
2001, doi: 10.1517/14656566.2.11.1795.
[26] F. Zanetti-Elshater, R. Pingitore, C. BerettaPiccoli, W. Riesen, and G. Heinen, “Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine.,” Am. J. Hypertens., vol. 7, no. 1, pp. 36– 45, Jan. 1994, doi: 10.1093/ajh/7.1.36.
[27] M. R. Law, N. J. Wald, J. K. Morris, and R. E. Jordan, “Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.,” BMJ, vol. 326, no. 7404, p. 1427, Jun. 2003, doi: 10.1136/bmj.326.7404.1427.
[28] M. Thoenes, H.-R. Neuberger, M. Volpe, B. V Khan, W. Kirch, and M. Bohm, “Antihypertensive drug therapy and blood pressure control in men and women: an international perspective.,” J. Hum. Hypertens., vol. 24, no. 5, pp. 336–344, May 2010, doi: 10.1038/jhh.2009.76.
[29] D. J. Campbell et al., “Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes.,” Intern. Med. J., vol. 43, no. 2, pp. 137–143, Feb. 2013, doi: 10.1111/j.1445-5994.2012.02927.x.
[30] J. Chalmers, H. Arima, S. Harrap, R. M. Touyz, and J. B. Park, “Global survey of current practice in management of hypertension as reported by societies affiliated with the International Society of Hypertension.,” J. Hypertens., vol. 31, no. 5, pp. 1043–
1048, May 2013, doi: 10.1097/HJH.0b013e32835f7eef.
[31] S. Bangalore, G. Kamalakkannan, S. Parkar, and F. H. Messerli, “Fixed-dose combinations improve medication compliance: a meta-analysis.,” Am. J. Med., vol. 120, no. 8, pp. 713–719, Aug. 2007, doi: 10.1016/j.amjmed.2006.08.033.
[32] A. K. Gupta, S. Arshad, and N. R. Poulter, “Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis.,” Hypertens. (Dallas, Tex. 1979), vol. 55, no.
2, pp. 399–407, Feb. 2010, doi:
10.1161/HYPERTENSIONAHA.109.139816.
[33] S. Yusuf et al., “Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.,” Lancet (London, England), vol. 373, no. 9672, pp. 1341–1351, Apr. 2009, doi: 10.1016/S0140-6736(09)60611-5.
[34] O. Mukhtar and S. H. D. Jackson, “The Hypertension in the Very Elderly Trial - latest data.,” Br. J. Clin. Pharmacol., vol. 75, no. 4, pp. 951–954, Apr. 2013, doi: 10.1111/j.1365-2125.2012.04427.x.
[2] M. H. Forouzanfar et al., “Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015,” JAMA, vol. 317, no. 2, pp. 165–182, Jan. 2017, doi: 10.1001/jama.2016.19043.
[3] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, “Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies,” Lancet, vol. 360, no. 9349, pp. 1903–1913, Dec. 2002, doi: 10.1016/S01406736(02)11911-8.
[4] B. Zhou et al., “Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with
19·1 million participants,” Lancet, vol. 389, no. 10064, pp. 37–55, Jan. 2017, doi: 10.1016/S01406736(16)31919-5.
[5] M. J. O’Donnell et al., “Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.,” Lancet (London, England), vol. 388, no. 10046, pp. 761–775, Aug. 2016, doi: 10.1016/S0140-6736(16)30506-2.
[6] E. Rapsomaniki et al., “Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people,” Lancet, vol. 383, no. 9932, pp. 1899–1911, May 2014, doi: 10.1016/S0140-6736(14)60685-1.
[7] C. Thomopoulos, G. Parati, and A. Zanchetti, “Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and meta-regression analyses of randomized trials.,” J. Hypertens., vol. 32, no. 12, pp. 2285–2295, Dec. 2014, doi: 10.1097/HJH.0000000000000378.
[8] W.-C. Tsai et al., “Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Metaanalysis.,” JAMA Intern. Med., vol. 177, no. 6, pp. 792–799, Jun. 2017,
doi: 10.1001/jamainternmed.2017.0197.
[9] S. Yusuf et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.,” Lancet (London, England), vol. 364, no. 9438, pp. 937–952, Sep. 2004, doi: 10.1016/S0140-6736(04)17018-9.
[10] J. R. Banegas et al., “Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.,” Eur. Heart J., vol. 32, no. 17, pp. 2143–2152, Sep. 2011, doi:
10.1093/eurheartj/ehr080.
[11] C. K. Chow et al., “Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.,” JAMA, vol. 310, no. 9, pp. 959–968, Sep. 2013, doi: 10.1001/jama.2013.184182.
[12] E. Falaschetti, J. Mindell, C. Knott, and N. Poulter, “Hypertension management in England: a serial cross-sectional study from 1994 to 2011,” Lancet, vol. 383, no. 9932, pp. 1912–1919, May 2014, doi: 10.1016/S0140-6736(14)60688-7.
[13] G. Tocci et al., “Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension.,” J. Hypertens., vol. 30, no. 6, pp.
1065–1074, Jun. 2012, doi:
10.1097/HJH.0b013e3283535993.
[14] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, “Global burden of hypertension: analysis of worldwide data.,” Lancet (London, England), vol. 365, no. 9455, pp. 217–223, Jan. 2005, doi: 10.1016/S0140-6736(05)17741-1.
[15] Y. R. Wang, G. C. Alexander, and R. S. Stafford, “Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States.,” Arch. Intern. Med., vol. 167, no. 2, pp. 141–147, Jan. 2007, doi: 10.1001/archinte.167.2.141.
[16] G. Corrao et al., “Better compliance to antihypertensive medications reduces cardiovascular risk.,” J. Hypertens., vol. 29, no. 3, pp. 610–618, Mar. 2011, doi: 10.1097/HJH.0b013e328342ca97.
[17] G. A. Mensah and G. Bakris, “Treatment and control of high blood pressure in adults.,” Cardiol. Clin., vol. 28, no. 4, pp. 609–622, Nov. 2010, doi: 10.1016/j.ccl.2010.08.002.
[18] P. Gupta et al., “Risk Factors for Nonadherence to Antihypertensive Treatment.,” Hypertens. (Dallas, Tex. 1979), vol. 69, no. 6, pp.
1113–1120, Jun. 2017, doi:
10.1161/HYPERTENSIONAHA.116.08729.
[19] J. van Gijn, “The PROGRESS Trial: preventing strokes by lowering blood pressure in patients with cerebral ischemia. Emerging therapies:
critique of an important advance.,” Stroke, vol. 33, no. 1, pp. 319–320, Jan. 2002.
[20] C. John et al., “Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus,” Hypertension, vol. 63, no. 2, pp. 259–264, Feb. 2014, doi: 10.1161/HYPERTENSIONAHA.113.02252.
[21] L. Opie, Ed., “No Title,” in Drugs for the heart, 4th ed., Philadelphia: WB Saunders Co., 1995, pp. 50–82.
[22] J. Webster, O. J. Robb, T. A. Jeffers, A. K. Scott, J. C. Petrie, and H. M. Towler, “Once daily amlodipine in the treatment of mild to moderate hypertension.,” Br. J. Clin. Pharmacol., vol. 24, no. 6, pp. 713–719, Dec. 1987, doi: 10.1111/j.13652125.1987.tb03236.x.
[23] B. Dahlof et al., “Cardiovascular morbidity
and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.,” Lancet (London, England), vol. 359, no. 9311, pp. 995–1003, Mar. 2002, doi: 10.1016/S0140-6736(02)08089-3.
[24] L. H. Lindholm et al., “Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol,” Lancet, vol. 359, no. 9311, pp. 1004–1010, Mar. 2002, doi: 10.1016/S0140-6736(02)08090-X.
[25] S. See, “Angiotensin II receptor blockers for the treatment of hypertension.,” Expert Opin. Pharmacother., vol. 2, no. 11, pp. 1795–1804, Nov.
2001, doi: 10.1517/14656566.2.11.1795.
[26] F. Zanetti-Elshater, R. Pingitore, C. BerettaPiccoli, W. Riesen, and G. Heinen, “Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine.,” Am. J. Hypertens., vol. 7, no. 1, pp. 36– 45, Jan. 1994, doi: 10.1093/ajh/7.1.36.
[27] M. R. Law, N. J. Wald, J. K. Morris, and R. E. Jordan, “Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.,” BMJ, vol. 326, no. 7404, p. 1427, Jun. 2003, doi: 10.1136/bmj.326.7404.1427.
[28] M. Thoenes, H.-R. Neuberger, M. Volpe, B. V Khan, W. Kirch, and M. Bohm, “Antihypertensive drug therapy and blood pressure control in men and women: an international perspective.,” J. Hum. Hypertens., vol. 24, no. 5, pp. 336–344, May 2010, doi: 10.1038/jhh.2009.76.
[29] D. J. Campbell et al., “Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes.,” Intern. Med. J., vol. 43, no. 2, pp. 137–143, Feb. 2013, doi: 10.1111/j.1445-5994.2012.02927.x.
[30] J. Chalmers, H. Arima, S. Harrap, R. M. Touyz, and J. B. Park, “Global survey of current practice in management of hypertension as reported by societies affiliated with the International Society of Hypertension.,” J. Hypertens., vol. 31, no. 5, pp. 1043–
1048, May 2013, doi: 10.1097/HJH.0b013e32835f7eef.
[31] S. Bangalore, G. Kamalakkannan, S. Parkar, and F. H. Messerli, “Fixed-dose combinations improve medication compliance: a meta-analysis.,” Am. J. Med., vol. 120, no. 8, pp. 713–719, Aug. 2007, doi: 10.1016/j.amjmed.2006.08.033.
[32] A. K. Gupta, S. Arshad, and N. R. Poulter, “Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis.,” Hypertens. (Dallas, Tex. 1979), vol. 55, no.
2, pp. 399–407, Feb. 2010, doi:
10.1161/HYPERTENSIONAHA.109.139816.
[33] S. Yusuf et al., “Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.,” Lancet (London, England), vol. 373, no. 9672, pp. 1341–1351, Apr. 2009, doi: 10.1016/S0140-6736(09)60611-5.
[34] O. Mukhtar and S. H. D. Jackson, “The Hypertension in the Very Elderly Trial - latest data.,” Br. J. Clin. Pharmacol., vol. 75, no. 4, pp. 951–954, Apr. 2013, doi: 10.1111/j.1365-2125.2012.04427.x.
Опубликован
2020-10-23
Как цитировать
Durgaryan, R., G. Manukyan, и A. Galadzhyan. 2020. «ЭФФЕКТИВНОСТЬ И СКЛОННОСТЬ К ЛЕЧЕНИЮ ФИКСИРОВАННОЙ ТРОЙНОЙ ТЕРАПИИ ПЕРИНОПРИЛ АРГИНИН / ИНДАПАМИД / АЛЛОДИПИН В НЕРЕГУЛИРУЕМОЙ ЦЕЛЕВОЙ ГРУППЕ, ПОЛУЧАЮЩЕЙ ДВУХКОМПОНЕНТНОЕ ЛЕЧЕНИЕ ЧЛЕНОВ ОРГАНИЗОВАННОЙ ПОПУЛЯЦИИ ». EurasianUnionScientists 2 (9(78), 20-25. https://archive.euroasia-science.ru/index.php/Euroasia/article/view/36.
Раздел
Статьи
CC BY-ND
Эта лицензия позволяет свободно распространять произведение, как на коммерческой, так некоммерческой основе, при этом работа должна оставаться неизменной и обязательно должно указываться авторство.
